CoChat

Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Nutrient excess, a major driver of obesity, diminishes hypothalamic responses to exogenously administered leptin, a critical hormone of energy balance. Here, we aimed to identify a physiological signal that arises from excess caloric intake and negatively controls hypothalamic leptin action. We found that deficiency of the gastric inhibitory polypeptide receptor (Gipr) for the gut-derived incretin hormone GIP protected against diet-induced neural leptin resistance. Furthermore, a centrally administered antibody that neutralizes GIPR had remarkable antiobesity effects in diet-induced obese mice, including reduced body weight and adiposity, and a decreased hypothalamic level of SOCS3, an inhibitor of leptin actions. In contrast, centrally administered GIP diminished hypothalamic sensitivity to leptin and increased hypothalamic levels of Socs3. Finally, we show that GIP increased the active form of the small GTPase Rap1 in the brain and that its activation was required for the central actions of GIP. Altogether, our results identify GIPR/Rap1 signaling in the brain as a molecular pathway linking overnutrition to the control of neural leptin actions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci126107

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Brain GIPR controls body weight and adiposity in obese mice. The GIPR monoclonal antibody Gipg013 was centrally infused (1 μg, every other day) into HFD-induced obese mice (A–C, 20 weeks of HFD feeding, n = 11–13), normal chow–fed (lean) mice (D–F, n = 6–7), and ob/ob mice (G–I, n = 8–9). Body weight (A, D, and G) and food intake (B, E, and H) were measured daily. Body composition (C, F, and I) was measured on day 14 of Gipg013 treatment. (J) Relative mRNA expression of the indicated genes in the hypothalamus after 15 days of Gipg013 injection. (K) Western blot quantification of SOCS-3 protein in the hypothalamus of Gipg013-treated mice (n = 7–13). β-Actin was used as a loading control. (L–N) HFD-induced obese mice fed for 49 weeks were i.c.v. infused with Gipg013 or control IgG (1 μg every 4 days, arrows) and in combination with an i.p. injection of liraglutide or saline (0.3 mg/kg once a day) (n = 9–11). (L) Body weight, (M) body weight change, and (N) food intake were measured during the treatment. Each data point represents the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 2-way ANOVA followed by Sidak’s multiple comparisons tests (A–I and L–N); 1-way ANOVA followed by Tukey’s multiple comparisons test (K); and t test (J).
Figure 1 Brain GIPR controls body weight and adiposity in obese mice. The GIPR monoclonal antibody Gipg013 was centrally infused (1 μg, every other day) into HFD-induced obese mice (A–C, 20 weeks of HFD feeding, n = 11–13), normal chow–fed (lean) mice (D–F, n = 6–7), and ob/ob mice (G–I, n = 8–9). Body weight (A, D, and G) and food intake (B, E, and H) were measured daily. Body composition (C, F, and I) was measured on day 14 of Gipg013 treatment. (J) Relative mRNA expression of the indicated genes in the hypothalamus after 15 days of Gipg013 injection. (K) Western blot quantification of SOCS-3 protein in the hypothalamus of Gipg013-treated mice (n = 7–13). β-Actin was used as a loading control. (L–N) HFD-induced obese mice fed for 49 weeks were i.c.v. infused with Gipg013 or control IgG (1 μg every 4 days, arrows) and in combination with an i.p. injection of liraglutide or saline (0.3 mg/kg once a day) (n = 9–11). (L) Body weight, (M) body weight change, and (N) food intake were measured during the treatment. Each data point represents the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 2-way ANOVA followed by Sidak’s multiple comparisons tests (A–I and L–N); 1-way ANOVA followed by Tukey’s multiple comparisons test (K); and t test (J).CC BY · PubMed Central
Figure 2 GIP negatively regulates neural leptin actions. (A and B) Leptin or vehicle was i.c.v. infused into WT and Gipr-KO mice after 4 weeks of a normal chow diet (A) or a HFD (B) (n = 7–11). Body weight and food intake were measured daily. (C) Normal chow–fed mice (n = 11–12, 16 weeks of age) were i.c.v. administered GIP (30 pmol/day) or vehicle. Leptin (5 μg/day) or vehicle was i.c.v. administered. Body weight and food intake were measured. (D) Mice (n = 3) were i.c.v. administered GIP or vehicle followed by leptin (5 μg) 3 hours later. p-STAT3 immunohistochemistry and quantification. Scale bar: 100 μm. (E) Electrophysiological recordings demonstrated that GIP pretreatment (6 h) occluded the leptin-induced depolarization of POMC neurons. The inhibitory effect of GIP on leptin-induced activation of POMC neurons is summarized in the histogram (n = 8–9). (F) GIP (administered i.c.v.) increased hypothalamic mRNA expression of Socs-3, Ptp1b, and Tcptp. Data are from 3 different experiments (n = 17–18). (G) Mice received once-daily i.p. injections of GIP for 3 days and then i.c.v. injections of leptin (5 μg) 2 hours after the last GIP injection. Body weight and food intake were measured 24 hours after leptin injection. n = 11 for groups without GIP treatment, n = 9 for GIP (30 pmol) treatment, and n = 4 for GIP (300 pmol) treatment. Each data point represents the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 compared with control mice, by 2-way ANOVA followed by Sidak’s multiple comparisons test (A–D and G); #P < 0.05, ##P < 0.01, ###P < 0.001, and ####P < 0.0001, compared with control mice on day 6 (A and B) and on day 3 (C), by 1-way ANOVA followed by Tukey’s multiple comparisons test; and *P < 0.05 and ***P < 0.001 compared with control, by t test (E and F). Data represent the mean ± SEM of 2 different experiments.
Figure 2 GIP negatively regulates neural leptin actions. (A and B) Leptin or vehicle was i.c.v. infused into WT and Gipr-KO mice after 4 weeks of a normal chow diet (A) or a HFD (B) (n = 7–11). Body weight and food intake were measured daily. (C) Normal chow–fed mice (n = 11–12, 16 weeks of age) were i.c.v. administered GIP (30 pmol/day) or vehicle. Leptin (5 μg/day) or vehicle was i.c.v. administered. Body weight and food intake were measured. (D) Mice (n = 3) were i.c.v. administered GIP or vehicle followed by leptin (5 μg) 3 hours later. p-STAT3 immunohistochemistry and quantification. Scale bar: 100 μm. (E) Electrophysiological recordings demonstrated that GIP pretreatment (6 h) occluded the leptin-induced depolarization of POMC neurons. The inhibitory effect of GIP on leptin-induced activation of POMC neurons is summarized in the histogram (n = 8–9). (F) GIP (administered i.c.v.) increased hypothalamic mRNA expression of Socs-3, Ptp1b, and Tcptp. Data are from 3 different experiments (n = 17–18). (G) Mice received once-daily i.p. injections of GIP for 3 days and then i.c.v. injections of leptin (5 μg) 2 hours after the last GIP injection. Body weight and food intake were measured 24 hours after leptin injection. n = 11 for groups without GIP treatment, n = 9 for GIP (30 pmol) treatment, and n = 4 for GIP (300 pmol) treatment. Each data point represents the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 compared with control mice, by 2-way ANOVA followed by Sidak’s multiple comparisons test (A–D and G); #P < 0.05, ##P < 0.01, ###P < 0.001, and ####P < 0.0001, compared with control mice on day 6 (A and B) and on day 3 (C), by 1-way ANOVA followed by Tukey’s multiple comparisons test; and *P < 0.05 and ***P < 0.001 compared with control, by t test (E and F). Data represent the mean ± SEM of 2 different experiments.CC BY · PubMed Central
Figure 3 Rap1 mediates the effects of centrally administered GIP. (A) Organotypic brain slices were incubated with GIP (0.5 μM, 6 h) and then stimulated with leptin (120 nM, 60 min). Images show p-STAT3 immunostaining of fixed slices. Scale bar: 100 μm. (B) GIP inhibited leptin-induced p-STAT3 in a dose- and time-dependent manner (n = 3–14). (C and D) Brain slices were incubated with GIP (0.5 μM), with or without 50 μM ESI-05 (C) or 10 μM PKI114–22 (D) for 6 hours and then stimulated with 120 nM leptin for 60 minutes. Representative images and quantification of hypothalamic p-STAT3 (n = 3–5) are shown. Scale bars: 100 μm. (E) Lean mice were i.c.v. administered GIP (3 nmol) for 2 hours. Left: Western blot images of active Rap1, total Rap1, and β-actin (n = 6). Middle: Quantification is shown from 3 independent experiments (n = 17–18). Right: Graph shows Rap1 activity in the brains of lean and obese mice treated with Gipg013 or control IgG (n = 7–10). (F and G) Rap1ΔCNS or control mice (n = 7–9) were i.c.v. injected with GIP (3 nmol/day) or vehicle and then i.c.v. injected with leptin (5 μg/day) 4 hours later. (F) Body weight change was measured daily. (G) Relative mRNA expression of the indicated genes in the hypothalamus of GIP- or vehicle-treated Rap1ΔCNS mice. Each data point represents the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by 1-way ANOVA followed by Tukey’s multiple comparisons test (B–E and G); **P < 0.01, by t test (E); and **P < 0.01, by 2-way ANOVA followed by Sidak’s multiple comparisons test (F). ARC, arcuate nucleus; 3V, third ventricle.
Figure 3 Rap1 mediates the effects of centrally administered GIP. (A) Organotypic brain slices were incubated with GIP (0.5 μM, 6 h) and then stimulated with leptin (120 nM, 60 min). Images show p-STAT3 immunostaining of fixed slices. Scale bar: 100 μm. (B) GIP inhibited leptin-induced p-STAT3 in a dose- and time-dependent manner (n = 3–14). (C and D) Brain slices were incubated with GIP (0.5 μM), with or without 50 μM ESI-05 (C) or 10 μM PKI114–22 (D) for 6 hours and then stimulated with 120 nM leptin for 60 minutes. Representative images and quantification of hypothalamic p-STAT3 (n = 3–5) are shown. Scale bars: 100 μm. (E) Lean mice were i.c.v. administered GIP (3 nmol) for 2 hours. Left: Western blot images of active Rap1, total Rap1, and β-actin (n = 6). Middle: Quantification is shown from 3 independent experiments (n = 17–18). Right: Graph shows Rap1 activity in the brains of lean and obese mice treated with Gipg013 or control IgG (n = 7–10). (F and G) Rap1ΔCNS or control mice (n = 7–9) were i.c.v. injected with GIP (3 nmol/day) or vehicle and then i.c.v. injected with leptin (5 μg/day) 4 hours later. (F) Body weight change was measured daily. (G) Relative mRNA expression of the indicated genes in the hypothalamus of GIP- or vehicle-treated Rap1ΔCNS mice. Each data point represents the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by 1-way ANOVA followed by Tukey’s multiple comparisons test (B–E and G); **P < 0.01, by t test (E); and **P < 0.01, by 2-way ANOVA followed by Sidak’s multiple comparisons test (F). ARC, arcuate nucleus; 3V, third ventricle.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 108

Metadata

Authors
Kaneko, K., Fu, Y., Lin, H.-Y., Cordonier, E. L., Mo, Q., Gao, Y., Yao, T., Naylor, J., Howard, V., Saito, K., Xu, P., Chen, S. S., Chen, M.-H., Xu, Y., Williams, K. W., Ravn, P., & Fukuda, M.
Affiliations
  • Baylor College of Medicine (US)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • The University of Texas Southwestern Medical Center (US)
  • AstraZeneca (United Kingdom) (GB)
  • AstraZeneca (United States) (US)
Corresponding author
Fukuda, Makoto
Venue
Journal of Clinical Investigation
Published
2019-08-12
Volume
129
Issue
9
Pages
3786-3791
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2967571306
Cited by
106
References
33
Citations by year
2026: 9 · 2025: 17 · 2024: 15 · 2023: 11 · 2022: 16 · 2021: 15 · 2020: 10 · 2019: 12
FWCI
7.32
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • NIH (5R01DK104901, P30-DK079638, DK119169, T32HD071839)
  • USDA/CRIS (ARS6250-51000-055, 6250-51000-059)
  • AHA (14BGIA20460080, 15POST22500012, 13POST13800000, 15POST22670017)
  • NIDDK (DK56338)
  • NCI (CA125123)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
Keywords
glucose-dependent insulinotropic polypeptide, GIP receptor, Rap1, leptin resistance, hypothalamus, overnutrition, diet-induced obesity, SOCS3, gut-brain signaling, incretins, energy balance, adiposity
MeSH terms
Suppressor of Cytokine Signaling 3 Protein, Animals, Hypothalamus, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Leptin, rap1 GTP-Binding Proteins, Adiposity, Mice, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.